GeNeuro Publishes Its 2021 Universal Registration Document
27 Avril 2022 - 6:26PM
Business Wire
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a
biopharmaceutical company developing treatments for
neurodegenerative and autoimmune diseases, such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe
neuropsychiatric consequences of COVID-19 (post-COVID),, publishes
its 2020 Universal Registration Document, in English, which has
been filed on April 27, 2022 with the “Autorité des Marchés
Financiers (AMF)”.
This document is available to the public free of charge, as
provided for in applicable legislation, and may be viewed and
downloaded on the Company’s website www.geneuro.com
The 2021 Universal Registration Document includes the annual
financial report in XBRL format, the auditors’ reports and
information about fees paid to statutory auditors, as well as the
draft resolutions to be submitted to the Annual Shareholders’
Meeting of May 31, 2022.
About GeNeuro GeNeuro‘s mission is to leverage HERV
biology to develop safe and effective treatments for the benefit of
patients, by neutralizing causal factors encoded by HERVs that
represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It has rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220427005911/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap (France) Louis-Victor Delouvrier / Mathilde Bohin
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 94
98 geneuro@newcap.eu
GeNeuro (EU:GNRO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
GeNeuro (EU:GNRO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024